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Abstract
Background: Liver-selective thyromimetics have been reported to efficiently reduce plasma cholesterol through the hepatic
induction of both, the low-density lipoprotein receptor (LDLr) and the high-density lipoprotein (HDL) receptor; the
scavenger receptor class B type I (SR-BI). Here, we investigated the effect of the thyromimetic T-0681 on reverse cholesterol
transport (RCT) and atherosclerosis, and studied the underlying mechanisms using different mouse models, including mice
lacking LDLr, SR-BI, and apoE, as well as CETP transgenic mice.
Methodology/Principal Findings: T-0681 treatment promoted bile acid production and biliary sterol secretion consistently
in the majority of the studied mouse models, which was associated with a marked reduction of plasma cholesterol. Using an
assay of macrophage RCT in mice, we found T-0681 to significantly increase fecal excretion of macrophage-derived neutral
and acidic sterols. No positive effect on RCT was found in CETP transgenic mice, most likely due to the observed decrease in
plasma CETP mass. Studies in SR-BI KO and LDLr KO mice suggested hepatic LDLr to be necessary for the action of T-0681
on lipid metabolism, as the compound did not have any influence on plasma cholesterol levels in mice lacking this receptor.
Finally, prolonged treatment with T-0681 reduced the development of atherosclerosis by 60% in apoE KOs on Western type
diet. In contrast, at an earlier time-point T-0681 slightly increased small fatty streak lesions, in part due to an impaired
macrophage cholesterol efflux capacity, when compared to controls.
Conclusions/Significance: The present results show that liver-selective thyromimetics can promote RCT and that such
compounds may protect from atherosclerosis partly through induction of bile acid metabolism and biliary sterol secretion.
On-going clinical trials will show whether selective thyromimetics do prevent atherosclerosis also in humans.
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Introduction
It has been known since 1930 that hyperthyroidism is associated
with reduced plasma cholesterol levels [1, reviewed in 2], and since
then many efforts were made to exploit the ability of thyroid
hormones (TH) to lower cholesterol. In the late 1960s, a large
clinical trial of dextrothyroxine (D-T4) therapy was conducted, as
part of The Coronary Drug Project by the National Institutes of
Health, which aimed to answer the question whether cholesterol
reduction may prevent coronary heart disease [3]. However, the
unfavorable recruitment of patients together with the accidental
employment of preparations contaminated with the enantiomer of
D-T4 resulted in a higher proportion of deaths in the D-T4 treated
group, leading to the discontinuation of clinical studies with TH
analogs in the 1970s [4,5]. With the introduction into clinical
practice of HMG-CoA reductase inhibitors, usually known as
‘statins’, to lower plasma cholesterol in the mid 1980s, efforts on
the development of TH analogs slowed. However, the last 20 years
saw the development of thyromimetic compounds selective for the
liver and/or the b1-isoform of the TH receptor which all were
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deleterious effects on the heart [4,5]. Several selective thyromi-
metics have been shown to be useful lipid-lowering compounds in
animal studies [6,7,8] resulting in clinical trials [9].
At present, it is believed that thyromimetics constitute useful
lipid-lowering therapeutic agents as they lead to a marked
reduction of low-density lipoprotein LDL cholesterol (LDL-C) by
enhancing the hepatic expression of the LDL receptor (LDLr)
[4,5]. Recently, it has been shown that liver-selective thyromi-
metics upregulate hepatic SR-BI, which is an important
component in reverse cholesterol transport (RCT) [7,10]. By their
dual action on LDL metabolism and RCT, thyromimetics could
be expected to counteract atherosclerosis.
In the present study, we investigated the effect of the liver-
selective thyromimetic T-0681 on RCT by measuring the
transport of cholesterol from macrophages to feces. We further
studied the impact of T-0681 on the development of atheroscle-
rosis in mice, and analyzed the underlying mechanisms.
Results
Effect of the Thyromimetic T-0681 on Lipid Metabolism
in Wild-Type Mice
In preliminary dose-titration studies in wild-type (WT) mice we
observed a marked increase of hepatic SR-BI expression at
36 nmol/kg/d T-0681, and a concomitant 50% decrease of
plasma cholesterol. Higher doses than 36 nmol/kg/d showed no
further lipid-lowering effect (data not shown). Accordingly, Parini
and coworkers recently presented data on SR-BI-inducing
properties of the thyromimetic GC-1 in liver of WT mice [7].
In subsequent experiments in WT mice, 36 nmol/kg/d of
T-0681 was found to reproducibly increase hepatic SR-BI
expression and to decrease both LDL-C and high-density
lipoprotein cholesterol (HDL-C, Figure 1A, B). This effect was
paralleled by decreased plasma contents of apoB and apoA-I
(Figure 1C). Real-Time PCR measurements of liver specimens
revealed increased mRNA levels of CYP7A1, the rate-limiting
enzyme for conversion of cholesterol into bile acids, and an
increased expression of hepatic ABCG5 and ABCG8, which are
known to promote biliary sterol secretion upon dimerization
(ABCG5/G8, Figure 1D) [11]. T-0681 treatment was associated
with increased fecal neutral sterol loss and strongly reduced
phytosterol levels in plasma (250%), which are known to reflect
intestinal cholesterol absorption (Figure 1E–F) [12].
No significant changes of the intestinal cholesterol transporters
ABCA1, ABCG5/G8 and Niemann-Pick C1 Like 1 [13,14] were
found (Figure 1G), no differences in food intake were observed
(data not shown).
Reverse Cholesterol Transport
Recently, Rader and coworkers developed the first in vivo
method to trace RCT specifically from macrophages to feces [15].
After intraperitoneal injection of [
3H]-cholesterol-labeled macro-
phages, the tracer is measured in plasma, liver, and feces. In our
experiments, T-0681 treated WT mice showed a strong decrease
of plasma [
3H]-cholesterol levels and no changes in hepatic tracer
content. Most importantly, fecal excretion of neutral and acidic
sterols was significantly increased in T-0681-treated animals
(Figure 2A). Similar effects were observed in macrophage RCT
studies using primary murine bone marrow-derived macrophages
(data not shown). Our data resemble the results from macrophage
RCT studies in SR-BI overexpressing animals [16]. In addition to
increased hepatic SR-BI expression, our mice also exhibited
increased hepatobiliary secretion of sterols via ABCG5/G8 and
CYP7A1, which may substantially contribute to the promotion of
RCT by T-0681.
RCT in humans is different from that found in rodents in that
cholesterol from the periphery can be transported to the liver
either directly via HDL particles or, after transfer to VLDL and
LDL mediated by the cholesteryl ester transfer protein (CETP), via
apoB-containing lipoproteins [17]. We therefore tested whether
treatment with a thyromimetic compound would also promote
RCT in an animal expressing CETP, and performed macrophage
RCT experiments in CETP transgenic mice (CETP Tg),
overexpressing human CETP under the control of its own
promoter. In CETP Tg mice, treatment with T-0681 significantly
reduced plasma cholesterol (8264 mg/dL vs. 5662 mg/dL,
control vs. T-0681, P,0.001). Plasma [
3H]-cholesterol levels
tended to be reduced (Figure 2B). However, there was no
significant increase in fecal [
3H]-sterol levels, although both SR-BI
as well as LDLrs were found increased in livers of T-0681 treated
animals (SR-BI 1.35-fold of controls, P=0.07; LDLr 1.8-fold of
controls, P,0.01; Figure 2B, inset). The appropriate delivery of
[
3H]-cholesterol to the liver may have been hampered by reduced
cholesteryl ester transfer from HDL to LDL/VLDL particles, as
suggested by reduced plasma CETP mass (1.7460.12 vs.
1.3860.12, control vs. T-0681, P=0.07). In addition, in contrast
to WT mice, no induction of hepatic CYP7A1 and ABCG5/G8
was observed (summarized in Table 1), which may have slowed
down the transport of [
3H]-sterols from the liver to the bile.
Relative Contribution of SR-BI and LDLr to the Effect of
T-0681 on Lipid Metabolism
Interestingly, we observed no effect of T-0681 on hepatic LDLr
expression of WT mice (data not shown). This finding is in
agreement with data by Parini and coworkers [7], but contrasts the
view of thyromimetics to act via induction of LDLr expression
[18].
Interestingly, we found a marked increase in LDLr expression in
the liver of CETP-expressing animals treated with T-0681,
including the here presented CETP Tg mice (Figure 2B, inset),
as well as in the recently studied hypercholesterolemic New
Zealand White (NZW) rabbits [10], which naturally express
plasma CETP. Moreover, T-0681 significantly increased hepatic
LDLrs in SR-BI KO mice (2-fold of controls, P,0.01), along with
a marked decrease in plasma cholesterol (Figure 3A). In contrast,
T-0681 did not affect plasma cholesterol in LDLr KO mice nor
did it induce the hepatic expression of SR-BI (Figure 3B).
Regulation of hepatic CYP7A1 and ABCG5/G8 is summarized in
Table 1.
The Dual Role of a Liver-Selective Thyromimetic on
Atherosclerosis
To study the impact of a selective thyromimetic on the
development of early atherosclerosis, apoE KO mice were fed a
Western type diet for 4 weeks and were concomitantly treated with
36 nmol/kg/d T-0681 or a placebo control. At study termination,
T-0681 treated animals showed a slight increase in mean
atherosclerotic lesion area on the one hand, and a decrease of
cholesterol in apoB-containing lipoproteins on the other hand
(Figure 4A, B); liver cholesterol was unaffected (1161 mg/g liver
vs. 1261 mg/g liver, control vs. T-0681, P=0.44). No difference
was observed in the hepatic expression of SR-BI, LDLr, ABCG5/
G8 and CYP7A1 (summarized in Table 1).
Prolonged treatment with T-0681 for 8 weeks strongly inhibited
the progression of atherosclerotic lesions in apoE KOs, as shown
in Figure 4C, D. The decrease in total plasma cholesterol was
T-0681 and Atherosclerosis
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lipid accumulation in the liver was clearly inhibited by T-0681
treatment (2662 mg cholesterol/g liver vs. 1362 mg cholesterol/
g liver, control vs. T-0681, P,0.001). There was no difference in
both hepatic SR-BI and LDLr protein expression. However, we
found a 3-fold upregulation of ABCG5, and a 2-fold increase of
CYP7A1 in livers of T-0681 treated apoE KOs (P,0.001 for both,
summarized in Table 1).
Influence of T-0681 on Macrophage SR-BI Expression and
on Plasma Cholesterol Efflux Capacity
To further understand the increase of small fatty streak lesions
at 4 weeks in apoE KO mice displaying reduced lipid levels, we
considered the analysis of the expression of cholesterol transporters
in macrophages, and tested the plasma efflux capacity of mice
from the 4-weeks and the 8-weeks study. As shown in Figure 5A,
we found a dose-dependent increase of the SR-BI protein
Figure 1. The liver-selective thyromimetic T-0681 promotes reverse cholesterol transport. Chow-fed WT mice were treated with T-0681
(36 nmol/kg/d) or PBS. (A) Western blot showing hepatic expression of SR-BI (N=6). (B) FPLC analysis of pooled plasma from control and T-0681-
treated mice (N=6). (C) Plasma concentrations of apoB and apoA-I (N=6). (D) Taqman real-time PCR analysis of hepatic ABCA1, ABCG5, ABCG8, and
CYP7A1 (N=4–10). (E) Analysis of fecal sterols (N=6), and (F), plasma levels of diet-derived phytosterols, normalized to cholesterol (N=5). (G) Taqman
real-time PCR analysis of intestinal cholesterol transporters ABCA1, ABCG5, ABCG8, and NPC1L1 (n=4–10). *P,0.05, **P,0.01, ***P,0.001 versus
corresponding controls; ns, non significant; data presented in % are normalized to the respective controls.
doi:10.1371/journal.pone.0008722.g001
T-0681 and Atherosclerosis
PLoS ONE | www.plosone.org 3 January 2010 | Volume 5 | Issue 1 | e8722expression in macrophages treated with T-0681, and no effect of
the thyromimetic on ABCA1 protein expression (not shown). SR-
BI is known to mediate either cholesterol uptake or efflux,
depending on the transmembrane cholesterol gradient [19,20]. In
our experiments, cholesterol efflux was significantly decreased in
macrophages treated with T-0681 and incubated with the
respective plasma from the 4-weeks study, compared to controls
(Figure 5B). Interestingly, there was no difference in cholesterol
efflux between controls and T-0681, when macrophages were
incubated with the respective plasma from the 8-weeks study
(Figure 5B). These findings suggest that, probably due to an
unfavorable plasma lipoprotein composition, macrophages within
the arterial wall may have been overloaded with cholesterol via
SR-BI.
Discussion
We previously showed that prolonged treatment with the liver-
selective thyromimetic T-0681 dramatically reduced the athero-
sclerotic lesion area in NZW rabbits [10]. Using another animal
model of dyslipemia, namely the apoE KO mouse, here again we
show that prolonged treatment with T-0681 reduces late
atherosclerosis development, which was associated with a decrease
in the circulating levels of pro-atherogenic apoB-containing
lipoproteins and increased hepatic expression of ABCG5/G8
and CYP7A1. Previously, ABCG5/G8 transgenic mice were
reported to display enhanced biliary cholesterol secretion,
increased neutral sterol loss via the feces, and strongly reduced
absorption of dietary sterols [11]. Interestingly, T-0681 treated
mice with increased ABCG5/G8 expression exhibited the same
characteristics. However, liver-specific overexpression of ABCG5/
G8 alone did not protect from atherosclerosis development [21].
T-0681 treated mice also showed enhanced conversion of
macrophage-derived cholesterol into bile acids via CYP7A1,
which constitutes a major pathway for cholesterol elimination.
Moreover, hepatic overexpression of CYP7A1 was previously
shown to significantly reduce plasma LDL-C levels [22]. In T-
0681 treated mice, hepatic LDLr seems to be essential for
functional bile acid synthesis as well as for biliary sterol secretion,
as we and others showed that thyromimetics do not affect plasma
cholesterol in LDLr KO mice [8].
Interestingly, after only 4 weeks of Western-type diet feeding, T-
0681 slightly increased the development of small fatty streak
lesions in apoE KO mice. There was a moderate decrease in
plasma cholesterol levels, and no change in hepatic LDLr, SR-BI,
ABCG5/G8 and CYP7A1 expression. In contrast to the 8-weeks
study, there was no reduction in hepatic cholesterol content in T-
0681 treated animals, which may have inhibited the induction of
the studied cholesterol receptors/transporters [10]. At the
moment, it remains elusive which mechanisms cause the decrease
in plasma cholesterol at the early 4-weeks time-point. Further
experiments are needed to elucidate the enterohepatic circulation
of bile acids as well as the absorption of dietary sterols in the
hyperlipidemic apoE KO model in more detail.
We further tried to understand the moderate increase in small
fatty streaks upon thyromimetic treatment observed in the 4-weeks
study. One possible explanation may be the fact that T-0681 was
found to increase SR-BI in macrophages, where this receptor was
shown to exert a dual role in atherosclerosis development. It is
known that SR-BI mediates cholesterol flux across the plasma
membrane, depending on the transmembrane cholesterol gradient
[19,20]. As suggested by the study of Van Eck and colleagues [23],
at an early stage of atherosclerosis, higher levels of SR-BI may
have promoted the (re-) uptake of cholesterol into macrophages. In
contrast, at 8 weeks of treatment, where markedly reduced levels
of cholesterol were found in the plasma of T-0681 treated mice,
increased macrophage SR-BI levels may not have affected the
efflux of cholesterol to HDL particles. Corroborating this view, T-
0681 significantly reduced the net cholesterol efflux from
macrophages to plasma of apoE KOs drawn at 4 weeks. In
contrast, T-0681 treated macrophages incubated with serum from
the 8-weeks study did not show alterations of net cholesterol efflux.
Although the induction of macrophage SR-BI together with an
Figure 2. Influence of T-0681 on macrophage reverse choles-
terol transport in vivo. (A) WT mice were treated with T-0681
(36 nmol/kg/d) or PBS, and the treatment was continued during the
48-hours RCT study. 12 days into treatment, cholesterol-loaded, [
3H]-
labeled J774 macrophages were injected intraperitoneally, and
48 hours later tracer was measured in plasma, liver, and fecal sterols
(N=10). (B) Macrophage in vivo RCT in CETP Tg mice was performed as
described in (A) (N=5); inset: Western blot showing hepatic expression
of LDLr and SR-BI; each lane represents pooled protein extracts from 5
mice per group. **P,0.01, ***P,0.001 versus corresponding control.
doi:10.1371/journal.pone.0008722.g002
Table 1. Hepatic regulation of SR-BI, LDLr, ABCG5/G8,
CYP7A1 by T-0681.
Mouse model SR-BI LDLr ABCG5/G8 CYP7A1
WT q 2 qq
SR-BI KO KO q qq qqq
LDLr KO 2 KO qq qq
CETP Tg qq22
apoE KO 4-wk 222 2
apoE KO 8-wk 22qq qq
The table summarizes the relative hepatic expression of the analyzed proteins
derived from all the experiments presented in this study. WT, wild-type mice;
KO, knock-out mice; 4-wk, 4 weeks study; 8-wk, 8 weeks study; 2, no change;
q, 1.5–2 - fold of control; qq, more than 2-fold of control; qqq, more than
4-fold of control.
doi:10.1371/journal.pone.0008722.t001
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part explain the divergent effects of T-0681 on atherosclerosis
development observed at different time-points, further studies are
necessary to understand which mechanisms are responsible for the
induction of the hepatobiliary sterol metabolism occurring
between 4 and 8 weeks of treatment, making thyromimetics either
pro- or anti-atherogenic.
Recently it was shown that functional reverse cholesterol
transport critically depends on biliary sterol secretion [24]. Thus,
induction of ABCG5/G8 and CYP7A1 may well have positively
influenced the RCT from macrophages to feces in our studies,
which was significantly promoted by T-0681. Interestingly, in
CETP Tg mice T-0681 increased hepatic SR-BI and LDLr, but
had no effect on hepatic ABCG5/G8 and CYP7A1. Moreover,
plasma CETP mass was decreased. Although there is functional
receptor-mediated cholesterol uptake in livers of CETP Tg mice,
the moderate decrease of plasma [
3H]-cholesterol by T-0681 in
the RCT study did not reach statistical significance, and fecal
output of [
3H]-sterols was found unaffected upon treatment.
Previously, Rader and coworkers clearly showed that in CETP Tg
mice a considerable amount of macrophage-derived [
3H]-
cholesterol is transferred from HDL to apoB-containing lipopro-
teins by CETP and subsequently cleared by the hepatic LDLr
[25]. Taken together, both decreased plasma CETP mass as well
Figure 3. Relative contribution of SR-BI and LDLr to the cholesterol-lowering action of T-0681. (A) FPLC analysis of pooled plasma from
SR-BI KO mice with and without T-0681 treatment (36 nmol/kg/d; N=4); inset: Western blot showing hepatic expression of LDLr; each lane represents
pooled protein extracts from 4 mice per group. (B) FPLC analysis of pooled plasma from LDLr KO mice with and without T-0681 treatment (36 nmol/
kg/d; N=4); inset: Western blot showing hepatic expression of SR-BI; each lane represents pooled protein extracts from 4 mice per group.
doi:10.1371/journal.pone.0008722.g003
Figure 4. Influence of T-0681 on atherosclerosis development in apoE KO mice. Western type diet-fed apoE KOs were treated with T-0681
(36 nmol/kg/d) or PBS for 4 weeks (A, B) (N=7) and 8 weeks (C, D) (N=10). (A, C) FPLC analysis of pooled plasma from control and T-0681-treated
mice. (B, D) Statistical comparison of the atherosclerotic lesion size in histological sections from the aortic root. ***P,0.001 versus corresponding
control.
doi:10.1371/journal.pone.0008722.g004
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RCT mechanism in T-0681 treated CETP Tg mice. Interestingly,
in our previous study in rabbits, we found no influence of the
employed thyromimetic on plasma CETP activity; thus, first
data on CETP function from the on-going clinical trials with
thyromimetics are heavily awaited, since impairment of CETP
activity may be deleterious in humans.
T-0681 treatment leads to increased LDLr expression in livers
of CETP Tg mice, in NZW rabbits which naturally express CETP
in plasma [10], and also in SR-BI KO mice, but not in livers of
WT mice or apoE KO mice on Western-type diet. It seems that
hepatic upregulation of LDLr by thyromimetics occurs when SR-
BI-mediated uptake of plasma cholesterol is reduced and/or
abolished, either through plasma CETP activity or due to the lack
of SR-BI.
In summary, the present study confirms the atheroprotective
properties of a prolonged treatment with T-0681. Our data
suggest that this pharmacological effect derives at least in part
from the modulation of hepatic ABCG5/G8 and CYP7A1
expression. This study also suggests that LDLr expression is
necessary for the lipid-lowering activity of selective thyromimetics.
However, further studies in LDLr KO and ABCG5 KO mice
would be helpful to clarify the specific role of the LDLr and of
biliary sterol secretion in the prevention of atherosclerosis
conferred by T-0681.
Materials and Methods
Reagents
The liver-selective thyromimetic T-0681 (former KAT-681)
[26] was kindly provided by Kissei Pharmaceutical Co., LTD,
Nagano, Japan.
Studies in WT, SR-BI KO, and LDLr KO Mice
All animals were handled in strict accordance with good animal
practice as defined by the Austrian Authorities, and all animal
work was approved by the Austrian Animal Care and Use
Committee. Male C57/B6 (WT) mice, obtained from Charles
River Laboratories (Kisslegg, Germany), were fed a standard chow
diet (Ssniff, Soest, Germany). After 2 weeks of acclimatization,
mice were divided into two groups and subcutaneously implanted
with Alzet micro-osmotic pumps (model 1002, Durect Corpora-
tion, Cupertino, CA, USA) carrying T-0681 in PBS (36 nmol/kg/
d) or PBS alone as control for 14 days. After 14 days of treatment,
animals were fasted for 5 h and anesthetized. Blood samples were
taken, mice sacrificed by cervical dislocation, and organ biopsies
were snap-frozen.
Male SR-BI KO and LDLr KO mice, obtained from Jackson
Laboratories (Bar Harbor, Maine, USA) were fed a standard chow
diet (Ssniff, Soest, Germany), and subcutaneously implanted with
Alzet micro-osmotic pumps (model 1002, Durect Corporation,
Cupertino, CA, USA) carrying T-0681 in PBS (36 nmol/kg/d) or
PBS alone as control. Mice were then fasted for 5 h, blood samples
were taken, mice were sacrificed by cervical dislocation, and liver
biopsies were snap-frozen.
Macrophage In Vivo RCT Studies in WT and CETP Tg Mice
J774 macrophages were obtained from the American Type
Culture Collection (ATCC, Manassas, VA, USA) and cultured in
supplemented DMEM medium (Invitrogen GIBCO, Carlsbad,
CA, USA) at 37uC and 5% CO2. Macrophage in vivo RCT studies
were performed as described [15,16,27]. In brief, male WT were
systemically treated with T-0681 (36 nmol/kg/d) or PBS for 14
days using Alzet micro-osmotic pumps as described above; the
treatment was continued during the 48-h RCT study. J774
macrophages were grown in suspension using a CELLspin 500
(Integra Biosciences, Chur, Switzerland) and radiolabeled with
2.5 mCi/ml [
3H]-cholesterol (PerkinElmer, Boston, MA, USA)
and 40 mg/ml acetylated LDL (AcLDL) [28] for 48 h. These foam
cells were washed twice, equilibrated in medium with 0.2% bovine
serum albumin for 6 h, spun down, and resuspended in PBS. The
cholesterol content of J774 foam cells was markedly elevated, and
the majority of cellular cholesterol was esterified (.80%), as
determined by thin-layer chromatography. On day 12, [
3H]-
cholesterol–labeled and AcLDL-loaded J774 cells (typically 8610
6
cells containing 2610
6 counts per minute [cpm] in 0.6 ml PBS)
were injected intraperitoneally. Feces were collected continuously
from 0 to 48 h and stored at 4uC before extraction of cholesterol
and bile acids. At study termination (48 h after injection), mice
were exsanguinated, perfused with cold PBS, and portions of the
liver were removed and snap-frozen. Liver lipid, fecal cholesterol
as well as bile acid extractions were performed as described [27].
Radioactivity in plasma, liver as well as fecal lipid extracts was
measured in a liquid scintillation counter. Macrophage in vivo
RCT studies in male CETP Tg mice [29] on regular chow diet
were carried out as described using 1610
6 J774 macrophages
containing 0.65610
6 cpm in 0.6 ml PBS.
Macrophage in vivo RCT studies in male WT mice with
primary murine bone marrow-derived macrophages (1610
6 cells
containing 0.6610
6 cpm in 0.6 ml PBS) were performed as
described elsewhere [30].
Cholesterol Efflux Studies
J774 macrophages were labeled with [
3H]-cholesterol (5 mCi/
ml [
3H]-cholesterol, PerkinElmer; 5 mg/ml ACAT inhibitor,
Sigma) for 48 h. Then cells were washed and equilibrated
overnight in either the presence or absence of T-0681 (100 nM)
in serum-free medium. For the cholesterol efflux, medium
containing 2.5% mouse plasma from the 4-weeks and the 8-weeks
studies was added to cells. After 4 hours, supernatant was collected
and centrifuged (5 min, 30006g, 4uC). Cells were washed with
PBS and lyzed in 1 ml 0.1 N NaOH. 300 ml of supernatant and
cell lysate were measured in a liquid scintillation counter.
Percentages of cholesterol efflux were calculated using following
formula:
% efflux~cpmsupernatant|100= cpmsupernatantzcpmcells

Figure 5. T-0681 increases macrophage SR-BI expression and
affects macrophage cholesterol efflux. (A) Western blot showing
expression of SR-BI in J774 macrophages treated with T-0681 at the
indicated concentrations for 24 h (N=3). (B) [
3H]-cholesterol labeled
J774 macrophages were treated with vehicle or 100nM T-0681 for 24 h,
after which they were incubated with 2.5% pooled mouse serum from
the 4-weeks and the 8-weeks study. Bars indicate mean [
3H]-cholesterol
efflux from triplicates. *P,0.05, **P,0.01 versus corresponding control.
doi:10.1371/journal.pone.0008722.g005
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Male apoE KO mice were obtained from Jackson Laboratories
(Bar Harbor, Maine, USA) After 2 weeks of acclimatization, mice
were set on a Western type diet (Ssniff, Soest, Germany), divided
into two groups and subcutaneously implanted with Alzet micro-
osmotic pumps (model 1004, Durect Corporation, Cupertino, CA,
USA) carrying T-0681 in PBS (36 nmol/kg/d) or PBS alone as
control. After 4 and 8 weeks, mice were fasted for 5 h, blood
samples were taken, mice sacrificed by cervical dislocation, and
liver biopsies were snap-frozen. Hearts were prepared and
atherosclerotic lesions quantified as described [31]. In brief, after
sacrifice by cervical dislocation, the heart of each animal was
perfused with 100 ml of PBS and fixed with 100 ml 4%
phosphate-buffered paraformaldehyde (pH 7.0) and serial 10-
mm-thick sections were cut between the valves and the aortic arch
for quantitative analysis of lipid deposition. On average, 180–200
slices were collected per mouse. For histological analyses, every
sixth slice was stained with Oil red-O and hematoxylin to identify
atheromatous lesions. Images were captured by use of a JVC
3-charge–coupled device video camera. Sections were analyzed
using the computer-assisted Quips Image analysis system (Leica
Mikroskopic and System GmbH, Wetzlar, Germany).
Lipid Parameters
Total cholesterol was measured in whole plasma of each animal
employing an ABX Diagnostics commercial kit (ABX Diagnostics,
Montpellier, France). Additionally, pooled plasma of each group
was subjected to FPLC fractionation analysis with two tandem
Superose 6 columns (GE Healthcare, Vienna, Austria) as
described previously [32]. Apolipoprotein measurements were
performed by an immunonephelometric assay as described [33].
Hepatic cholesterol content was measured as described [34].
CETP mass was determined using a previously developed ELISA
[35].
Fecal Sterol Analysis
50 mg of dried feces were boiled in 1 ml alkaline methanol (1M
NaOH/Methanol, 1:3 v/v) at 80uC for 2 h after addition of
50 nmol 5a-Cholestane as internal standard for neutral sterol
analysis. After cooling down to room temperature, neutral sterols
were extracted using three times 3 ml of petroleum ether, boiling
range 60–80uC. The residual sample was diluted 1:9 with distilled
water. 100 ml of the solution were subjected to an enzymatic total
bile acid measurement [36]. The extracted neutral sterols were
converted to trimethylsilyl derivatives. Neutral sterol composition
of prepared feces samples was determined by capillary gas
chromatography on an Agilent gas chromatograph (HP 6890,
Hewlett Packard, Palo Alto, CA, USA) equipped with a
25 m60.25 mm CP-Sil-19 fused silica column (Varian, Middel-
burg, The Netherlands) and a Flame Ionization Detector. The
working conditions were the following: Injector temperature
280uC; pressure 16.0 psi; column flow constant at 0.8 ml/min;
oven temperature program: 240uC (4 min), 10uC/min to 280uC
(27 min); detector temperature 300uC.
Plant Sterol Measurement in Plasma
Sitosterol and campesterol were extracted from 10 ml plasma
from each animal in duplicate samples. Samples were derivatized
with trimethylsilane reagent (pyridin:hexametyldisilan:trimetyl-
chlorosilane 3:2:1, v/v/v) prior to gas-chromatography-mass
spectrometry analysis [37]. D5-campesterol/sitosterol was used
as internal standard. The levels of sitosterol and campesterol in
plasma reflect cholesterol absorption [12].
Protein Extraction and Western Blot Analysis
Preparation of proteins from murine liver samples as well as
from T-0681-treated J774 macrophages and subsequent Western
blot analysis were performed as described [32]. Murine SR-BI was
detected using NB 400-104 (Novus Biologicals, Littleton, CO,
USA), ABCA1 was tested with a polyclonal rabbit anti-ABCA1
antibody (NB 400–105; Novus Biologicals). Anti-LDLr antibody
was a generous gift from J. Herz [38]. The chemoluminescent
reaction was performed using Super Signal West Dura Reagent
(Pierce, Rockford, IL, USA) and blots were visualized by Fluor-S-
Imager using Quantity One V4.1 software (BioRad, Hercules, CA,
USA).
RNA Isolation, Reverse Transcription, and Quantitative
Real-Time PCR
Total RNA was extracted using RNA bee according to the
manufacturer’s protocol (Tel-test Inc., Friendswood, Texas, USA)
and reverse transcribed with Omniscript-RT Kit (Qiagen, Hilden,
Germany). Primers and probes for murine ABCA1, ABCG5,
ABCG8, CYP7A1 were described previously [27], primers and
probes for murine NPC1L1 elsewhere [39]. GUSB and HPRT
were used as reference (Applied Biosystems, Foster City, CA,
USA). Taqman real-time PCR reactions were performed on a
Mx4000H Multiplex Quantitative PCR System (Stratagene,
Amsterdam, The Netherlands).
Statistics
Results are presented as mean 6 s.e.m. The statistical signi-
ficance of the differences between the means of the experimental
groups was tested by the Student’s t-test for unpaired data. A
difference was considered statistically significant when P,0.05.
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